We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Less than 24 hours after finalizing its acquisition of Allergan’s generics division, Teva Pharmaceutical disclosed plans to pick up the company’s distribution arm for $500 million. Read More
After nearly two years, the EMA is formalizing its iterative pathway program that saw six applications progress to formal advice from the agency, according to a report. Read More
The FDA is simplifying the process of developing written procedures for an IRB, providing industry with a comprehensive checklist that satisfies both FDA and HHS requirements. Read More
The FDA is confronting institutional drawbacks to developing combination products with a pilot program meant to improve the current review process. Read More